Truist Financial has increased its price target for Addus HomeCare Corporation from $135 to $148, while reiterating a 'Buy' rating. This positive adjustment follows the company's Q3 2026 earnings report, suggesting analyst confidence in future performance.
Truist Financial has raised its price target for Addus HomeCare (ADUS) from $135 to $148 and maintained its 'Buy' rating. This upgrade comes after the company's third-quarter 2026 earnings report, indicating that analysts view the recent financial performance positively and anticipate continued growth. For traders, this signals a potential upside for ADUS shares in the short to medium term, as analyst upgrades often provide a positive sentiment boost. The key opportunity lies in potential price appreciation driven by increased investor confidence, though market reactions to analyst revisions can vary.